Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
07/26/07	₩1,721.00	+0.23%	5,582
06/26/06	₩1,717.00	+0.18%	5,703
03/26/03	₩1,714.00	-0.98%	7,410
02/26/02	₩1,731.00	0.00%	8,587
01/26/01	₩1,731.00	-0.86%	11,895

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 07/07/2026			5-day change	1st Jan Change
1,721.00 ^KRW	+0.23%		-1.71%	-65.58%

01/07	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
26/05	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI

Market Cap	1.9TCr 1.25Cr 1.1Cr 1.01Cr 93.74L 1.78Cr 119.02Cr 1.81Cr 12Cr 4.72Cr 59Cr 4.71Cr 4.61Cr 203.03Cr	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	180.36Cr 11.91L 10.42L 10L 9L 16.9L 11Cr 17.17L 1.15Cr 44.78L 5.58Cr 44.7L 43.73L 19Cr	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

01/07	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
26/05	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
14/05	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
08/05	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
07/05	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
28/04	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
28/04	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
20/03	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
16/03	APTOCROM Inc. announces Annual dividend	CI
13/11	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/25/13	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25/25/25	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
22/25/22	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

1 day	+0.23%
1 week	-1.71%
Current month	-1.43%
1 month	-13.65%
3 months	-48.47%
6 months	-67.03%
Current year	-65.58%

APTOCROM Inc. Share Price

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,630	1,790
1 month	1,630	1,992
Current year	1,630	5,400
1 year	1,630	11,820
3 years	1,630	49,900
5 years	1,630	1,13,000
10 years	1,630	4,26,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	23/03/2022
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-
Jong-Su Kang SAM	Sales & Marketing	62	-

Director	Title	Age	Since
Soon-Kyu Park BRD	Director/Board Member	59	-
Jung-Chool Kim BRD	Director/Board Member	70	23/03/2022
Jae-Seob Kim BRD	Director/Board Member	63	10/01/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	+0.23%	-1.71%	-73.84%	-93.79%	1.24Cr
ELI LILLY AND COMPANY	+2.92%	+2.83%	+59.58%	+172.82%	1,07000Cr
JOHNSON & JOHNSON	+2.95%	+5.02%	+71.78%	+67.49%	62TCr
ABBVIE INC.	-0.02%	+1.23%	+35.76%	+87.99%	45TCr
ROCHE HOLDING AG	+2.14%	-2.07%	+27.62%	+22.57%	33TCr
ASTRAZENECA PLC	+1.87%	+1.87%	+40.58%	+42.08%	29TCr
NOVARTIS AG	+1.36%	+0.17%	+29.90%	+49.33%	28TCr
NOVO NORDISK A/S	+1.98%	+4.08%	-25.78%	-39.02%	22TCr
AMGEN INC.	+0.24%	+1.33%	+25.26%	+67.82%	20TCr
GILEAD SCIENCES, INC.	+4.21%	+6.97%	+20.90%	+81.59%	16TCr
Average	+1.81%	+0.82%	+21.17%	+45.89%	36.24TCr
Weighted average by Cap.	+2.15%	+0.70%	+43.27%	+87.86%

	2024	2025
Net sales	1.64TCr 1.08Cr 94.75L 87.32L 80.93L 1.54Cr 102.76Cr 1.56Cr 10Cr 4.07Cr 51Cr 4.06Cr 3.98Cr 175.28Cr	980.73Cr 64.74L 56.66L 52.22L 48.4L 91.87L 61Cr 93.36L 6.26Cr 2.43Cr 30Cr 2.43Cr 2.38Cr 104.82Cr
Net income	-2.81TCr -1.85Cr -1.62Cr -1.5Cr -1.39Cr -2.63Cr -176.02Cr -2.67Cr -18Cr -6.97Cr -87Cr -6.96Cr -6.81Cr -300.26Cr	-555.94Cr -36.7L -32.12L -29.6L -27.44L -52.08L -35Cr -52.92L -3.55Cr -1.38Cr -17Cr -1.38Cr -1.35Cr -59Cr
Net Debt	-2.51TCr -1.65Cr -1.45Cr -1.33Cr -1.24Cr -2.35Cr -157.06Cr -2.39Cr -16Cr -6.22Cr -78Cr -6.21Cr -6.08Cr -267.92Cr	-1.72TCr -1.13Cr -99.32L -91.54L -84.84L -1.61Cr -107.72Cr -1.64Cr -11Cr -4.27Cr -53Cr -4.26Cr -4.17Cr -183.75Cr